Mulpleo (previously Lusutrombopag Shionogi)

On 14 April 2026, the European Commission withdrew the marketing authorisation for Mulpleo (lusutrombopag) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Shionogi B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Mulpleo was granted marketing authorisation in the EU on 18 February 2019 to prevent excessive bleeding in adults with thrombocytopenia due to long\-standing liver disease. The marketing authorisation was initially valid for a 5\-year period. It was then granted unlimited validity in 2023\.